Archived News Releases

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

12/06/24

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

12/03/24

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

11/14/24

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

11/12/24

Pacira BioSciences Reports Third Quarter 2024 Financial Results

11/06/24

Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings

11/04/24

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

10/30/24

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

10/21/24

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

10/07/24

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

10/03/24

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

09/26/24

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

09/09/24

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

08/09/24

Pacira BioSciences Reports Second Quarter 2024 Financial Results

07/30/24

Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

07/23/24

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

07/10/24

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

05/30/24

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

05/10/24

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

05/08/24

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

05/07/24

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

05/07/24

Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024

04/30/24

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

04/02/24

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

03/13/24

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

03/06/24

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

02/29/24

Pacira to Report 2023 Financial Results on Thursday February 29, 2024

02/22/24

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

02/15/24

Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.

02/07/24

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

01/04/24

Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

01/03/24